Pipeline - Ocugenix

Preclinical
IND-Enabling
Phase 1
Phase 2
Phase 3

Retinal Fibro-Vascular Disease

Wet AMD

Preclinical
IND-Enabling
Phase 1
Phase 2
Phase 3

OGX110

Proliferative Diabetic Retinopathy

Preclinical
IND-Enabling
Phase 1
Phase 2
Phase 3

OGX110

Geographic Atrophy

Preclinical
IND-Enabling
Phase 1
Phase 2
Phase 3

OGX110

Ocular Surface Inflammatory Disease

Dry Eye

Preclinical
IND-Enabling
Phase 1
Phase 2
Phase 3

OGX117

Intellectual Property & Patents

Worldwide Composition of Matter patents granted (OGX110)
Worldwide Method of Action patents granted (therapeutic use of CXCR3 agonism)
NCE (New Chemical Entity) designation — provides regulatory exclusivity protection through 2043
OGX110 is the only CXCR3 agonist currently in clinical trials for retinal disease

Ian P. Conner, M.D., Ph.D.

Founder and Clinical Advisor

Dr. Ian Conner is an assistant professor of ophthalmology and bioengineering at the University of Pittsburgh and the director of the UPMC Eye Center. Through an unrestricted grant from the Research to Prevent Blindness (RPB), Dr. Conner has collaborated with faculty members affiliated with the McGowan Institute for Regenerative Medicine to investigate the structural, metabolic, and functional relationships between the eye and the brain in glaucoma. In addition to his research efforts, Dr. Conner has served as site investigator on several UPMC Eye Center clinical studies on glaucoma and ocular hypertension.

Cecelia C. Yates, Ph.D.

Founder and Scientific Advisor

Dr. Cecilia Yates is an associate professor of health promotion and development at UPMC School of Nursing. Dr. Yates’ research focuses on chemokine and extracellular matrix interactions in systemic sclerosis (scleroderma) and idiopathic pulmonary fibrosis in the development of dermal and pulmonary fibrosis. She has a cellular and molecular laboratory fully equipped for basic and translational research located within the School of Nursing. Current members of the laboratory are investigating genomic regulation of molecules that mediate the development and progression of fibrosis. Dr. Yates is also developing small molecule therapeutics and cellular therapies to improve tissue remodeling.

Alan Wells, M.D., DMS

Founder and Chief Scientific Officer

Dr. Alan Wells is the Thomas J. Gill III Professor of Pathology and the executive vice-chairman of the department of pathology at the University of Pittsburgh. In addition, Dr. Wells is a professor of bioengineering and computational & systems biology (secondary appointments) and a staff physician at the Veterans Administration Medical Center in Pittsburgh, Pennsylvania. Dr. Wells holds an AB in biochemistry from Brown University (1979) and received his DMS in tumor biology from the Karolinska Institute in Stockholm, Sweden, in 1982. Returning to Providence, Rhode Island, he received his MD from Brown University in 1988. Following his studies, Dr. Wells completed a postdoctoral fellowship in tumor biology at the University of California in San Francisco, California, and a residency in laboratory medicine at the University of California in San Diego, California.

Sean McDonald

Founder and Chief Executive Officer

Sean McDonald has a track record of building start-ups from early stages of venture capital investment to self-sufficient revenue generation. He previously led Precision Therapeutics, a market-leading personalized medicine company, that he grew through both internal development as well as acquisitions to $40 million in revenue.

During Mr. McDonald’s tenure as CEO, Precision Therapeutics developed the most diversified portfolio in the industry of validated personalized medicine products impacting lung, colon and gynecological cancers. Earlier in his career, he founded Automated Healthcare, a company that developed the first systems that automated the dispensing of medications in hospital pharmacies. The system has been successfully deployed in several hundred hospital pharmacies across the country and dispenses a half a billion prescriptions. Mr. McDonald grew that business from startup to close to $200 million in revenue.